Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study to Evaluate Take Rate, Immunogenicity and Safety of Bavarian Nordic's Smallpox Vaccine Elstree-BN Administered to Healthy Vaccinia-Naive Subjects in the Age of 18-32 Years

NCT00189969 is registered in ClinicalTrials.gov with Bavarian Nordic as lead sponsor.

NCT NCT00189969
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00189969 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study to Evaluate Take Rate, Immunogenicity and Safety of Bavarian Nordic's Smallpox Vaccine Elstree-BN Administered to Healthy Vaccinia-Naive Subjects in the Age of 18-32 Years
Lead sponsor
Bavarian Nordic
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2003
Completion date
February 28, 2006
Enrollment
50
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

smallpox